This content is machine translated Blastic plasmacytoid dendritic cell neoplasia Rare malignancy from a dermatological perspective Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is an aggressive hematologic malignancy originating from immature plasmacytoid dendritic cell (PDC) precursors. The initial manifestation of BPDCN often consists of cutaneous lesions. In...… CME-Test
View Post 6 min This content is machine translated EHA 2025 Progress in multiple myeloma The annual meeting of the European Hematology Association (EHA) has been one of the most important focal points for international haematology for many years. With more than 15,000 participants on...…
View Post 10 min This content is machine translated Electrolyte disturbance Hyponatremia in the outpatient setting Over the last two decades, the evidence has become increasingly clear that even relatively mild hyponatremia without obvious or severe symptoms is clinically relevant. It leads to neurocognitive impairments, gait...… CME-Test
View Post 8 min This content is machine translated ASCO 2025 Supportive therapies for greater adherence and compliance ASCO 2025 is the annual meeting of the American Society of Clinical Oncology (ASCO), which took place in Chicago from May 30 to June 3. In this section, we take...…
View Post 7 min This content is machine translated Diabetes-related cardiovascular diseases Ferroptosis: key mechanisms and novel therapeutic approaches The global increase in diabetes mellitus is leading to a parallel increase in the incidence of cardiovascular complications, which remain the leading cause of death in this patient group. In...…
View Post 16 min This content is machine translated Blastic plasmacytoid dendritic cell neoplasia Rare malignancy from a dermatological perspective Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is an aggressive hematologic malignancy originating from immature plasmacytoid dendritic cell (PDC) precursors. The initial manifestation of BPDCN often consists of cutaneous lesions. In...… CME-Test
View Post 5 min This content is machine translated Multiple myeloma DREAMM-7: Belamaf plus bortezomib and dexamethasone outperforms comparator therapy In patients with multiple myeloma, the disease is often refractory to first-line triple or quadruple therapies. The result: a relapse occurs. Therefore, effective second-line therapy combinations are needed that include...…
View Post 2 min This content is machine translated Acute myeloid leukemia The influence of time from diagnosis to treatment on overall survival Acute myeloid leukemia (AML) is often classified as an oncologic emergency leading to rapid evaluation and treatment in the hospital. Previous studies reported that time from diagnosis to treatment (TDT)...…
View Post 2 min This content is machine translated Acute lymphoblastic leukemia Addition of blinatumomab to chemotherapy improves survival in children Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) with standard risk (SR) have a high survival rate when treated...…
View Post 3 min This content is machine translated Hodgkin's lymphoma No more transplants for relapsed or refractory HL in the future? The standard treatment approach for relapsed or refractory (RR) classical Hodgkin’s lymphoma (HL) after failure of first-line treatment is second-line therapy with the aim of achieving complete remission (CR), followed...…
View Post 2 min This content is machine translated Smoldering multiple myeloma Daratumumab delays progression in smoldering multiple myeloma Smoldering multiple myeloma (SMM) is an asymptomatic premalignant precursor of active multiple myeloma (MM). Results of the presented phase III AQUILA study show that daratumumab significantly delays the progression of...…
